Finally, we validated that VNP-siALKBH5 plus Oxaliplatin also markedly reduced tumor growth (Fig. 8N) along with down-regulation of β-catenin, LGR5 and CD133 (Fig. 8O and Fig. S13G) and induction of cell apoptosis (Fig. 8O and Fig. S13H) in CSC28, indicating in vivo siALKBH5 enhances chemotherapy efficacy in CRC. The gene discussed is LGR5; the disease is neoplasm.